May E. Venturanza

597 total citations · 1 hit paper
33 papers, 453 citations indexed

About

May E. Venturanza is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, May E. Venturanza has authored 33 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Dermatology, 27 papers in Immunology and Allergy and 10 papers in Physiology. Recurrent topics in May E. Venturanza's work include Dermatology and Skin Diseases (32 papers), Allergic Rhinitis and Sensitization (19 papers) and Food Allergy and Anaphylaxis Research (9 papers). May E. Venturanza is often cited by papers focused on Dermatology and Skin Diseases (32 papers), Allergic Rhinitis and Sensitization (19 papers) and Food Allergy and Anaphylaxis Research (9 papers). May E. Venturanza collaborates with scholars based in United States, Canada and Poland. May E. Venturanza's co-authors include Michael E. Kuligowski, Kang Sun, Kim Papp, Eric L. Simpson, Jacek C. Szepietowski, Leon Kircik, Lawrence F. Eichenfield, Darryl Toth, Seth Forman and Donald Y.M. Leung and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Journal of Investigative Dermatology and Journal of the American Academy of Dermatology.

In The Last Decade

May E. Venturanza

32 papers receiving 440 citations

Hit Papers

Efficacy and safety of ruxolitinib cream for the treatmen... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
    2021 199 citations Kim Papp, Jacek C. Szepietowski et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
May E. Venturanza United States 9 382 302 95 89 50 33 453
Nathalie Barbier Switzerland 11 748 2.0× 627 2.1× 63 0.7× 145 1.6× 52 1.0× 19 832
Natália C. Couto-Francisco United Kingdom 5 146 0.4× 441 1.5× 31 0.3× 241 2.7× 89 1.8× 6 515
Jeremy Udkoff United States 10 324 0.8× 244 0.8× 60 0.6× 89 1.0× 34 0.7× 27 420
Eileen Jaracz United States 14 681 1.8× 537 1.8× 41 0.4× 77 0.9× 62 1.2× 16 756
Hany Elmaraghy United States 9 315 0.8× 118 0.4× 66 0.7× 82 0.9× 261 5.2× 30 419
Alexander Salava Finland 10 185 0.5× 85 0.3× 14 0.1× 41 0.5× 36 0.7× 35 359
Carla Riccardi Italy 11 88 0.2× 302 1.0× 21 0.2× 130 1.5× 37 0.7× 32 423
José Carlos Armario Hita Spain 13 307 0.8× 149 0.5× 78 0.8× 112 1.3× 145 2.9× 55 405
Tamara Quint Austria 9 150 0.4× 121 0.4× 24 0.3× 109 1.2× 80 1.6× 11 320
Bridget Kaufman United States 6 373 1.0× 177 0.6× 45 0.5× 77 0.9× 86 1.7× 15 445

Countries citing papers authored by May E. Venturanza

Since Specialization
Citations

This map shows the geographic impact of May E. Venturanza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by May E. Venturanza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites May E. Venturanza more than expected).

Fields of papers citing papers by May E. Venturanza

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by May E. Venturanza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by May E. Venturanza. The network helps show where May E. Venturanza may publish in the future.

Co-authorship network of co-authors of May E. Venturanza

This figure shows the co-authorship network connecting the top 25 collaborators of May E. Venturanza. A scholar is included among the top collaborators of May E. Venturanza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with May E. Venturanza. May E. Venturanza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eichenfield, Lawrence F., Eric L. Simpson, Kim Papp, et al.. (2024). Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. American Journal of Clinical Dermatology. 25(4). 669–683. 8 indexed citations
2.
Blauvelt, Andrew, Leon Kircik, Kim Papp, et al.. (2022). Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 37(1). 137–146. 15 indexed citations
3.
Eichenfield, Lawrence F., Linda Stein Gold, Kanwaljit Brar, et al.. (2022). 275 Effects of ruxolitinib cream on sleep and quality of life over 52 weeks in black patients with atopic dermatitis. Journal of Investigative Dermatology. 142(8). S47–S47. 1 indexed citations
4.
Leung, Donald Y.M., Amy S. Paller, Andrea L. Zaenglein, et al.. (2022). Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis. Annals of Allergy Asthma & Immunology. 130(4). 500–507.e3. 13 indexed citations
5.
Blauvelt, Andrew, Jacek C. Szepietowski, Kim Papp, et al.. (2022). Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studies. Journal of the American Academy of Dermatology. 88(3). 651–653. 9 indexed citations
6.
Simpson, Eric L., Kim Papp, Jacek C. Szepietowski, et al.. (2022). Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine. 6(2). s28–s28. 1 indexed citations
7.
Blauvelt, Andrew, Jacek C. Szepietowski, Kim Papp, et al.. (2021). 325 Ruxolitinib cream rapidly decreases skin pain in atopic dermatitis. Journal of Investigative Dermatology. 141(5). S57–S57. 2 indexed citations
8.
Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2021). Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies. SKIN The Journal of Cutaneous Medicine. 5(1). s8–s8. 1 indexed citations
9.
Simpson, Eric L., Robert Bissonnette, Michael E. Kuligowski, et al.. (2021). 311 Effects of ruxolitinib cream in patients with atopic dermatitis with head and/or neck involvement. Journal of Investigative Dermatology. 141(5). S55–S55. 2 indexed citations
10.
Simpson, Eric L., et al.. (2021). 329 Efficacy of ruxolitinib cream in adults and adolescents with atopic comorbidities. Journal of Investigative Dermatology. 141(5). S58–S58. 2 indexed citations
11.
Blauvelt, Andrew, Jacek C. Szepietowski, Kim Papp, et al.. (2021). 26884 Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: Pooled results from two phase 3 studies. Journal of the American Academy of Dermatology. 85(3). AB121–AB121. 9 indexed citations
12.
Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2021). Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. Journal of the American Academy of Dermatology. 85(4). 863–872. 199 indexed citations breakdown →
13.
Blauvelt, Andrew, Jacek C. Szepietowski, Kim Papp, et al.. (2021). 313 Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream. Journal of Investigative Dermatology. 141(5). S55–S55. 1 indexed citations
14.
Simpson, Eric L., Robert Bissonnette, Michael E. Kuligowski, et al.. (2021). Effects of Ruxolitinib Cream in Patients With Atopic Dermatitis With Head and/or Neck Involvement. SKIN The Journal of Cutaneous Medicine. 5(6). s67–s67. 1 indexed citations
15.
Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2021). Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine. 5(6). s63–s63. 1 indexed citations
16.
Simpson, Eric L., Leon Kircik, Andrew Blauvelt, et al.. (2021). Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine. 5(6). s66–s66.
17.
Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2021). 27716 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline clinical characteristics: Pooled subgroup analysis from two randomized phase 3 studies. Journal of the American Academy of Dermatology. 85(3). AB160–AB160. 3 indexed citations
18.
Kim, Brian, Kang Sun, Kim Papp, et al.. (2020). Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. Journal of the American Academy of Dermatology. 82(6). 1305–1313. 81 indexed citations
19.
Owens, Sherry, et al.. (2019). 998 Ruxolitinib cream significantly modulates inflammatory profiles of atopic dermatitis patients. Journal of Investigative Dermatology. 139(5). S173–S173. 4 indexed citations
20.
Rose, Keith, S. P. Cooper, May E. Venturanza, et al.. (2014). Simulation-Based Training for Nurses in Sterile Techniques During Central Vein Catheterization. American Journal of Critical Care. 23(1). 40–48. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nathalie Barbier Breakdown of academic impact, for papers by Natália C. Couto-Francisco Breakdown of academic impact, for papers by Jeremy Udkoff Breakdown of academic impact, for papers by Eileen Jaracz Breakdown of academic impact, for papers by Hany Elmaraghy Breakdown of academic impact, for papers by Alexander Salava Breakdown of academic impact, for papers by Carla Riccardi Breakdown of academic impact, for papers by José Carlos Armario Hita Breakdown of academic impact, for papers by Tamara Quint Breakdown of academic impact, for papers by Bridget Kaufman
Rankless by CCL
2026